Hepatic Arterial and Systemic Chemotherapy for the Treatment of Primary and Secondary Malignancies of the Liver

Twenty-two patients with metastatic and primary cancer of the liver were treated with 5-fluoro-2′-deoxyuridine (5FUDR), Mitomycin C (Mito C), and 1 (-2-chlorethyl)-4(methyl-cyclohexyl)-l-nitrosourea (MeCCNU). 5FUDR 0.3 mg/kg/ day was administered as a continuous infusion via the hepatic artery. Mito C (10 mg/M²) and MeCCNU (50 mg/M² ) were given I.V. and orally, respectively, every 8 weeks. Remission of the neoplastic lesions within the liver was seen in 10 patients (4CR, 6PR). Five patients had stabilization of their lesion neoplasm for at least 4 months.

The response rate in this study was 6/15 (40%) in patients with colon cancer metastatic to the liver. Toxicity was mainly hematologic and hepatic. Three patients experienced a platelet count below 25,000 and/or white blood count below 1000. Fifteen patients had hepatic toxicity showing elevation in SGOT and SGPT. The SGOT and SGPT returned to normal when the 5FUDR was discontinued. The combination of 5FUDR intraarterially, and Mito C and MeCCNU systemically, demonstrated activity in malignancies of the liver. This study proved that chemotherapy can be administered systemically and regionally with acceptable toxicity.